• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Lorlatinib and Bevacizumab Activity in Rearranged Lung Cancers After Lorlatinib Progression.

作者信息

Choudhury Noura J, Young Robert J, Sellitti Matthew, Miller Alexandra, Drilon Alexander

机构信息

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.

出版信息

JCO Precis Oncol. 2020 Nov 2;4. doi: 10.1200/PO.20.00271. eCollection 2020.

DOI:10.1200/PO.20.00271
PMID:33283131
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7713518/
Abstract
摘要

相似文献

1
Lorlatinib and Bevacizumab Activity in Rearranged Lung Cancers After Lorlatinib Progression.劳拉替尼进展后，劳拉替尼与贝伐单抗在重排型肺癌中的活性。
JCO Precis Oncol. 2020 Nov 2;4. doi: 10.1200/PO.20.00271. eCollection 2020.
2
Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.洛拉替尼治疗既往治疗的间变性淋巴瘤激酶重排的非小细胞肺癌：全球研究的日本亚组分析。
Cancer Sci. 2020 Oct;111(10):3726-3738. doi: 10.1111/cas.14576. Epub 2020 Sep 11.
3
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.ALK 重排肺癌中对第三代 ALK 抑制剂洛拉替尼的多种耐药机制。
Clin Cancer Res. 2020 Jan 1;26(1):242-255. doi: 10.1158/1078-0432.CCR-19-1104. Epub 2019 Oct 4.
4
Safety of lorlatinib following alectinib-induced pneumonitis in two patients with -rearranged non-small cell lung cancer: a case series.在两名ALK重排的非小细胞肺癌患者中，阿来替尼诱发肺炎后使用劳拉替尼的安全性：病例系列
Transl Lung Cancer Res. 2021 Jan;10(1):487-495. doi: 10.21037/tlcr-20-564.
5
Symptomatic CNS Radiation Necrosis Requiring Neurosurgical Resection During Treatment with Lorlatinib in -Rearranged NSCLC: A Report of Two Cases.在接受劳拉替尼治疗的间变性淋巴瘤激酶重排非小细胞肺癌中出现需要神经外科切除的症状性中枢神经系统放射性坏死：两例报告
Lung Cancer (Auckl). 2020 Jan 14;11:13-18. doi: 10.2147/LCTT.S224991. eCollection 2020.
6
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.劳拉替尼用于治疗具有ALK或ROS1重排的非小细胞肺癌：一项国际多中心、开放标签、单臂首次人体1期试验。
Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23.
7
Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.获得性多重突变 ALK I1171N、L1196M 和 G1202R 介导 EML4-ALK 重排恶性胸膜间皮瘤对 lorlatinib 的耐药性：一例报告。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620935770. doi: 10.1177/1753466620935770.
8
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.洛拉替尼治疗 ALK 阳性非小细胞肺癌患者的疗效：一项全球性 2 期研究结果。
Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6.
9
Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date.聚焦劳拉替尼及其在非小细胞肺癌治疗中的潜力：迄今的证据
Onco Targets Ther. 2018 Aug 22;11:5093-5101. doi: 10.2147/OTT.S165511. eCollection 2018.
10
Rapid regression of neurological symptoms in patients with metastasised ALK+ lung cancer who are treated with lorlatinib: a report of two cases.接受劳拉替尼治疗的转移性ALK+肺癌患者神经症状迅速缓解：两例报告
BMJ Case Rep. 2019 Jul 24;12(7):e227299. doi: 10.1136/bcr-2018-227299.

引用本文的文献

1
New advances in understanding the mechanisms and treatment challenges of ALK-targeted therapy resistance in lung cancer.肺癌中ALK靶向治疗耐药的机制及治疗挑战的新进展
Cancer Drug Resist. 2025 Aug 25;8:43. doi: 10.20517/cdr.2025.122. eCollection 2025.
2
Prognostic significance of clonal hematopoiesis in STEMI: a 10-year follow-up reveals high-risk gene mutations.ST段抬高型心肌梗死中克隆性造血的预后意义：一项10年随访揭示高危基因突变
Hum Genomics. 2025 May 12;19(1):51. doi: 10.1186/s40246-025-00757-2.
3
Case report: Precise NGS and combined bevacizumab promote durable response in ALK-positive lung adenocarcinoma with multiple-line ALK-TKI resistance.病例报告：精准的下一代测序（NGS）联合贝伐单抗可促进对多线ALK酪氨酸激酶抑制剂（ALK-TKI）耐药的ALK阳性肺腺癌产生持久反应。
Front Oncol. 2024 Jun 24;14:1419306. doi: 10.3389/fonc.2024.1419306. eCollection 2024.
4
Toxic Erythema of Chemotherapy, Vasculitic Eruption With Malignant Intertrigo Characteristics, and Superimposed Infection Post-bevacizumab Initiation.化疗所致中毒性红斑、具有恶性擦烂特征的血管性皮疹以及贝伐单抗开始使用后并发感染
Cureus. 2024 Jan 23;16(1):e52816. doi: 10.7759/cureus.52816. eCollection 2024 Jan.
5
Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions.揭示ALK靶向治疗在非小细胞肺癌中的潜力：全面见解与未来方向
Biomedicines. 2024 Jan 27;12(2):297. doi: 10.3390/biomedicines12020297.
6
Advances in the Management of Central Nervous System Metastases in Non-Small Cell Lung Cancer.非小细胞肺癌中枢神经系统转移的管理进展
Cancers (Basel). 2023 Jan 30;15(3):844. doi: 10.3390/cancers15030844.
7
Anti-Angiogenic Therapy in Rearranged Non-Small Cell Lung Cancer (NSCLC).抗血管生成治疗在非小细胞肺癌（NSCLC）中的应用。
Int J Mol Sci. 2022 Aug 9;23(16):8863. doi: 10.3390/ijms23168863.
8
Anaplastic lymphoma kinase-special immunity and immunotherapy.间变性淋巴瘤激酶-特异性免疫与免疫治疗。
Front Immunol. 2022 Jul 25;13:908894. doi: 10.3389/fimmu.2022.908894. eCollection 2022.
9
Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study.阿来替尼联合贝伐珠单抗治疗晚期 ALK 重排非小细胞肺癌患者的安全性和活性：一项 I/II 期研究。
ESMO Open. 2022 Feb;7(1):100342. doi: 10.1016/j.esmoop.2021.100342. Epub 2021 Dec 9.

本文引用的文献

1
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer.洛拉替尼在既往治疗的 ALK 阳性非小细胞肺癌患者中的脑渗透：CNS 和非 CNS 进展的累积发生率与洛拉替尼相关。
Target Oncol. 2020 Feb;15(1):55-65. doi: 10.1007/s11523-020-00702-4.
2
Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases.贝伐单抗联合培美曲塞和铂类显著改善了晚期腺癌非小细胞肺癌伴脑转移患者的临床结局。
Cancer Manag Res. 2019 Nov 29;11:10083-10092. doi: 10.2147/CMAR.S222910. eCollection 2019.
3
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.雷莫芦单抗联合厄洛替尼治疗未经治疗的表皮生长因子受体突变型、晚期非小细胞肺癌患者（RELAY）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4.
4
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.ALK 重排肺癌中对第三代 ALK 抑制剂洛拉替尼的多种耐药机制。
Clin Cancer Res. 2020 Jan 1;26(1):242-255. doi: 10.1158/1078-0432.CCR-19-1104. Epub 2019 Oct 4.
5
Treatment with Next-Generation ALK Inhibitors Fuels Plasma Mutation Diversity.新一代 ALK 抑制剂治疗引发血浆基因突变多样性。
Clin Cancer Res. 2019 Nov 15;25(22):6662-6670. doi: 10.1158/1078-0432.CCR-19-1436. Epub 2019 Jul 29.
6
Primary Resistance to Alectinib Was Lost after Bevacizumab Combined Chemotherapy in ALK-Rearranged Lung Adenocarcinoma.在贝伐单抗联合化疗后，ALK重排肺腺癌对阿来替尼的原发性耐药消失。
J Thorac Oncol. 2019 Aug;14(8):e168-e169. doi: 10.1016/j.jtho.2019.03.009.
7
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.厄洛替尼联合贝伐珠单抗对比厄洛替尼单药治疗表皮生长因子受体阳性的晚期非鳞状非小细胞肺癌（NEJ026）：一项开放标签、随机、多中心、III 期临床试验的期中分析。
Lancet Oncol. 2019 May;20(5):625-635. doi: 10.1016/S1470-2045(19)30035-X. Epub 2019 Apr 8.
8
Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.晚期间变性淋巴瘤激酶阳性非小细胞肺癌中洛拉替尼的耐药突变与疗效。
J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20.
9
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.洛拉替尼治疗 ALK 阳性非小细胞肺癌患者的疗效：一项全球性 2 期研究结果。
Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6.
10
Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.洛拉替尼治疗在 ALK 驱动的癌症中引发多种靶内和靶外耐药机制。
Cancer Res. 2018 Dec 15;78(24):6866-6880. doi: 10.1158/0008-5472.CAN-18-1867. Epub 2018 Oct 15.